作者
PJ Hayden, C Roddie, P Bader, GW Basak, H Bonig, C Bonini, C Chabannon, F Ciceri, S Corbacioglu, R Ellard, F Sanchez-Guijo, U Jäger, M Hildebrandt, M Hudecek, MJ Kersten, Ulrike Köhl, J Kuball, S Mielke, M Mohty, J Murray, A Nagler, J Rees, C Rioufol, R Saccardi, JA Snowden, J Styczynski, M Subklewe, C Thieblemont, M Topp, ÁU Ispizua, D Chen, Radovan Vrhovac, JG Gribben, N Kröger, H Einsele, I Yakoub-Agha
发表日期
2022/3/1
期刊
Annals of Oncology
卷号
33
期号
3
页码范围
259-275
出版商
Elsevier
简介
Background
Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future.
Design
The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field.
Results
Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all …
学术搜索中的文章
PJ Hayden, C Roddie, P Bader, GW Basak, H Bonig… - Annals of Oncology, 2022